Clinical characteristics | All (83) | Optimal (52) | Suboptimal (31) | P |
---|---|---|---|---|
Age | 53.75 ± 10.51 | 52.13 ± 9.81 | 56.45 ± 11.24 | 0.070 |
FIGO stage | ||||
III | 74 (89.16%) | 46 (88.46%) | 28 (90.32%) | 0.791 |
IV | 9 (10.84%) | 6 (11.54%) | 3 (9.68%) | |
Tumor grade | ||||
1–2 | 28 (33.73%) | 18 (34.62%) | 10 (32.26%) | 0.826 |
3 | 55 (66.27%) | 34 (65.38%) | 21 (67.74%) | |
Histology | ||||
Serous | 68 (81.93%) | 45 (86.54%) | 23 (74.19%) | 0.157 |
Others | 15 (18.07%) | 7 (13.46%) | 8 (25.81%) | |
Preoperative serum CA125 level(U/ml) | 1260.84 ± 1542.01 | 1285.57 ± 1662.24 | 1219.36 ± 1341.36 | 0.851 |
Preoperative serum HE4 level (pmol/L) | 635.65 ± 749.15 | 419.96 ± 355.56 | 997.44 ± 1050.33 | 0.006* |
ECOG performance status | ||||
0 | 69 (83.13%) | 45 (86.54%) | 24 (77.42%) | 0.131 |
1 | 9 (10.84%) | 6 (11.54%) | 3 (9.68%) | |
2 | 5 (6.03%) | 1 (1.92%) | 4 (12.90%) | |
ASA | ||||
1 | 9 (10.84%) | 5 (9.61%) | 4 (12.90%) | 0.886 |
2 | 69 (83.13%) | 44 (84.62%) | 25 (80.65%) | |
≥ 3 | 5 (6.03%) | 3 (5.77%) | 2 (6.45%) |